Loading...
NPI 1053584482 · Brooklyn, NY · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Empire City Laboratories, Inc is a clinical medical laboratory provider located in Brooklyn, New York. This profile covers 298 Medicare and 429 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Empire City Laboratories, Inc |
| Address | 229 49th St |
| City | Brooklyn |
| State | NY |
| ZIP | 11220 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | April 7, 2008 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $143M |
| Medicare | $6.7M |
EMPIRE CITY LABORATORIES, INC is a high-volume clinical diagnostic laboratory with an 18-year NPI tenure (enumerated 2008-04-07). The dominant test mix — including high volumes of vitamin D testing (82306), TSH and thyroid panels (84443, 84439), lipid panels (80061), CMPs (80053), A1C (83036), and infectious disease nucleic acid assays (U0003, U0005, 87502) — indicates a broad outpatient laboratory services operation that supports routine chronic disease monitoring, population screening, and high-throughput infectious disease testing. The combination of routine chemistry/endocrine panels and multiplex molecular infectious assays suggests both general clinical lab services and significant molecular testing capacity.
Medicaid revenue ($143M) dwarfs Medicare revenue ($6.7M), making the provider effectively Medicaid-dominant in scale. The provider’s Medicaid book accounts for the vast majority of lifetime revenue reported, indicating its business is concentrated on patients and contracts that bill Medicaid at scale rather than on Medicare. Analysts should treat this entity as primarily a Medicaid-focused testing vendor when evaluating regional network capacity or contracting exposure.
Revenue concentration differs by payer: the precomputed top-three codes account for 26.8% of this provider’s total Medicare revenue and 40.8% of its total Medicaid revenue. For Medicare the revenue is more dispersed across many common lab codes, while Medicaid billing shows a heavier concentration in a small set of high-volume codes (notably U0003, 82306, and 87633), implying that a handful of service lines drive a large share of Medicaid dollars for this facility.
Competitive standing versus peers is pronounced and payer-specific. For Medicare, multiple routine chemistry and endocrine codes (82306, 84443, 80061, 80053, 83036, 85025) are at or near the 100th national percentile and described as "notably above typical" or "extreme outlier" volumes, indicating this provider is a major national-volume submitter for several common lab tests. For Medicaid the provider ranks at the top statewide for many codes (e.g., 82306 and multiple infectious disease panels ranked #1 in-state) and is repeatedly described as an "extreme outlier, far above typical state volume," establishing it as a dominant in-state player for both routine panels and COVID/respiratory-related testing.
The provider is an extreme high-volume statewide supplier for molecular infectious testing under Medicaid: U0003 (438.8K claims, $28.1M revenue) ranks #3 in-state and is labeled an "extreme outlier, far above typical state volume," while U0005 (327.6K claims, $5.2M revenue) and serologic antibody testing 86769 (155K claims, $4.8M revenue) are also top contributors. These figures show substantial capacity for high-throughput SARS-CoV-2 nucleic acid and antibody testing, suggesting contracts or specimen routing that generate very large Medicaid testing volumes.
Specific Medicare codes show exceptional national standing for certain specialized tests: 87502 (2.7K claims, $252.3K revenue) ranks #14 nationally and is labeled an "extreme outlier, far above typical national volume," and 86409 (929 claims, $95.7K revenue) ranks #1 nationally. Those rankings indicate the lab handles unusually large volumes of particular molecular and serologic infectious assays relative to national peers, implying specialized molecular workflow or referral testing for these assays.
The code-level mix reflects both routine ambulatory monitoring and public health-related screening. High counts for A1C (83036), lipid panels (80061), CMP (80053), CBC (85025), and urinalysis (81001 in Medicaid) point to steady chronic disease surveillance and primary care support. Simultaneously, massive Medicaid volumes in STI NAATs (87491, 87591), respiratory panels (87633, 87502, 87634), and COVID NAATs/antibody tests (U0003, U0005, ) indicate the lab also functions as a regional hub for infectious disease diagnostics and public-health-related specimen processing.
Several codes are flagged as statistical outliers or extreme outliers in rank/percentile language provided, which reinforces the lab’s atypically large role in specific testing categories. Examples include Medicaid 82306 and many state-leading codes described as "extreme outlier, far above typical state volume," and Medicare-level outliers such as 87502 and 86409 described as "extreme outlier, far above typical national volume." These descriptors should guide competitive assessments and capacity models rather than implying quality issues.
Given the mix of very large Medicaid volumes and comparatively small Medicare revenue, payer negotiation and network impact will be most material on the Medicaid side. Contracting, reimbursement changes, or state program shifts affecting high-volume Medicaid codes (notably U0003, 82306, 80050, and 87633) could materially affect the provider’s revenue base, whereas Medicare-facing risk or leverage is relatively limited by comparison.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
298 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 15,090 | $30 | $437.5K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 23,880 | $20 | $382.1K |
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 25,010 | $10 | $325.1K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 28,470 | $10 | $284.7K |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 2,680 | $90 | $252.3K |
| 83036 | Sugar in the bloodstream can get attached to the hemoglobin in red blood cells. Once the sugar is attached, it stays there for the lifetime of the red blood cell (around 120 days or over 3 months).… | 25,040 | $10 | $250.4K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 29,240 | $10 | $233.9K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 2,910 | $70 | $212.5K |
| 82607 | The lab analyst performs a test to measure the amount of vitamin B12 in a patient specimen, typically in patient blood. | 13,320 | $20 | $199.8K |
| 87634 | The lab analyst performs a test for respiratory syncytial virus (RSV) antigen detection using amplified nucleic acid probe technique. | 2,400 | $70 | $165.5K |
Showing 1–10 of 298
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 298 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
298 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| P9604 | 7 | 10 | 1,880 | $20 | $306.6K |
| 87798 | 11 | 40 | 740 | $30 | $218.3K |
| 88120 | 22 | 30 | 90 | $450 | $133.6K |
| 86409 | 1 | 10 | 930 | $100 | $95.9K |
| 87507 | 2 | 10 | 120 | $410 | $83.7K |
| G0483 | 12 | 20 | 270 | $240 | $82.4K |
| G0480 | 9 | 30 | 170 | $110 | $76.5K |
| 87581 | 8 | 10 | 350 | $30 | $64.6K |
| 87486 | 8 | 10 | 350 | $30 | $64.2K |
| 88305 | 342 | 980 | 370 | $50 | $58.5K |
Showing 1–10 of 298
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
429 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 438,780 | $60 | $28.1M |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 36,050 | $210 | $7.7M |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 420,750 | $20 | $6.7M |
| 80050 | The lab analyst performs testing for the specific group of clinical laboratory procedures in the general health panel. Payers typically consider 80050 to apply only when the clinician orders the… | 266,120 | $20 | $5.3M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 327,570 | $20 | $5.2M |
| 86769 | The lab analyst performs a multiple–step immunoassay to evaluate the patient’s serum for antibodies to severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), which causes coronavirus disease… | 154,970 | $30 | $4.8M |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 133,060 | $30 | $4.4M |
| 86481 | The lab analyst performs a test to evaluate an antigen response to certain tuberculosis (TB) antibodies by enumerating T cells that produce gamma interferon. | 132,590 | $30 | $4.2M |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 281,120 | $10 | $3.9M |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 275,250 | $10 | $3.9M |
Showing 1–10 of 429
How this provider's Medicaid billing volume and revenue compare to other New York providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New York median
429 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 3 | 340 | 1,090 | $70 | $1.4M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 86 | 100 | 1,490 | $70 | $1.3M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 28 | 40 | 440 | $90 | $511.9K |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 4 | 140 | 360 | $130 | $492.1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 6 | 300 | 1,710 | $20 | $458.6K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 5 | 110 | 690 | $50 | $442K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 6 | 290 | 1,900 | $30 | $390.6K |
| 86409 | The lab analyst performs the technical lab test to analyze the titer (concentration) of neutralizing antibodies in a specimen such as plasma. The level of these antibodies indicates a past infection… | 1 | 10 | 9,790 | $40 | $383K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 3 | 30 | 550 | $100 | $359.8K |
| 81220 | The lab analyst performs the technical lab test to detect the presence of changes in the gene for cystic fibrosis transmembrane conductance regulator, also known as CFTR. The test evaluates the CFTR… | 43 | 60 | 230 | $370 | $340.9K |
Showing 1–10 of 429
Other providers in the same ZIP code as Empire City Laboratories, Inc, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Nyu Langone Hospitals | NY | General Acute Care Hospital | $0 | $303.2M |
| Allstar Homecare Agency, Inc | NY | Home Health Agency | $0 | $234.3M |
| Allstar Homecare Fi, Inc. | NY | Personal Care Attendant | $0 | $147.9M |
| Platinum Home Health Care Inc. Cdpap | NY | Home Health Agency | $0 | $36M |
| Reliance Home Care Inc. | NY | Home Health Agency | $0 | $32.2M |
| Jy Adult Social Day Care Service, Inc. | NY | Adult Day Care Clinic/Center | $0 | $32.1M |
| Reliance Fi LLC | NY | Case Management Agency | $0 | $32.1M |
| Family Respite Homecare Agency Inc. | NY | Home Health Agency | $0 | $30.8M |
| Dart Medical Laboratory, Inc | NY | Clinical Medical Laboratory | $767.2K | $27.1M |
| Healthy Family Social Daycare Inc | NY | Adult Day Care Clinic/Center | $0 | $27.2M |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.